

# Long-Acting Injectable (LAI) Buprenorphine for Opioid Use Disorder (OUD)

*The LAI Advantage.*

## Overview What is Long-Acting Buprenorphine?

Next-generation formulation that releases buprenorphine over an extended period of time, enabling sustained therapeutic levels to be maintained without daily dosing.<sup>1,2</sup>

### Meeting the Need

- Enables disease management vs. crisis-based care<sup>1,2,3,4</sup>
- Creates savings from lower overdose rates, fewer hospitalizations, and reduced recidivism<sup>5</sup>
- Addresses low treatment retention<sup>1,4,6</sup>
- Reduces burden of daily visits or doses<sup>1,3,7</sup>
- Blocks rewarding effects of opioids (including fentanyl)<sup>8</sup>
- Reduces risk of diversion<sup>2,9</sup>

## Patients and Communities Benefit from Using LAIs as a Primary Care Option

Patients with OUD show improved adherence and treatment satisfaction with LAI formulations.<sup>4,7,10</sup>

### Number of Treatment Days is Reduced with Use of Monthly LAIs<sup>3</sup>

Max Dose\*



**365**  
doses/year




Min Dose\*



**10-12**  
doses/year

Illustrative comparison of typical dosing schedules for orally-administered medicines and monthly LAIs.


\*Possible for patients to dose oral treatments more than once per day.



## Why LAIs Fit Well in Criminal Justice Settings

-  Offers simple medication administration (fewer events) and logistics<sup>1,3,5,7,11</sup>
-  Supports individuals through custody transitions<sup>6,9</sup>
-  Decreases the risk of diversion<sup>2,9</sup>
-  Reduces the risk of overdose deaths during high-risk, post-release period<sup>5,9,11</sup>
-  Blocks rewarding effects of opioids (including fentanyl)<sup>9</sup>
-  Promotes positive re-entry outcomes including employment, relationships, and reduced future justice system involvement<sup>6,9</sup>

## Studies Show Cost Savings from Combining Medical Therapy with Behavioral Programs<sup>12</sup>



**Broadening access to long-acting injectable buprenorphine strengthens public health outcomes and improves chances for long-term recovery.**

1. ScienceInsights. "How Do Long-Acting Injectable Medications Work?" Science Insights, Nov. 16, 2025. <https://scienceinsights.org/how-do-long-acting-injectable-medications-work/>
2. Nordgren, J., et al. "Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study." Pub Med Central, April 5, 2024. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10996245/>
3. Allen, Susie. "Within Reach." The University of Chicago Magazine, Summer 2024, <https://mag.uchicago.edu/science-medicine/within-reach>
4. Compton, Wilson M., and Volkow, Nora D. "Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes." JAMA Network Open, May 10, 2021. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779757>
5. Huxley-Reicher, Z., et al. "Extending Knowledge of LAI Buprenorphine with Dr. Ken Lee." The Curbsiders Addiction Medicine Podcast, August 31, 2023. <https://thecurbsiders.com/addiction-medicine-podcast/20-extending-knowledge-of-lai-buprenorphine-with-dr-ken-lee>
6. Lee, Joshua D., et al. "Comparison of Treatment Retention of Adults with Opioid Addiction Managed with Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release from Jail." JAMA Network Open, Sept. 8, 2021. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784022>
7. Allen, E., et al. "Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study." Drug and Alcohol Review, Feb. 14, 2023. <https://onlinelibrary.wiley.com/doi/10.1111/dar.13616>
8. Shiwach, R., et al., "Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use." JAMA Network Open, Dec.17, 2025. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842881>
9. Flanagan, E., et al., "Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails." JAMA Network Open, April 16, 2025. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832851>
10. Kuhns, Lisa. "Long-Acting Injectable Antipsychotics Reduce 30-Day Rehospitalizations." Psychiatry Advisor, Feb. 27, 2024. <https://www.psychiatryadvisor.com/news/long-acting-injectable-antipsychotics/>
11. Washington State Health Care Authority. "Recommendations on alternative models for long-acting injectable buprenorphine." Washington State Health Care Authority, Oct. 15, 2024 <https://www.hca.wa.gov/assets/program/long-acting-injectable-buprenorphine-leg-report-2024.pdf>
12. Avalere Health. "The cost of addiction: Opioid use disorder in the United States." Avalere Health, May 2025. [https://advisory.avalerehealth.com/wp-content/uploads/2025/05/Avalere-Health-White-Paper\\_The-cost-of-opioid-addiction\\_OUD-in-the-United-States.pdf](https://advisory.avalerehealth.com/wp-content/uploads/2025/05/Avalere-Health-White-Paper_The-cost-of-opioid-addiction_OUD-in-the-United-States.pdf)